PHATHOM PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$7.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-30
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$132.00K, a 108.44% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$6.92M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $2.13M, a 63.91% decline year-over-year.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.39M.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$5.51M, a 171.86% decline from fiscal 2024.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $7.67M, a 4.90% decline from fiscal 2023.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $8.07M, a 333.71% increase from fiscal 2022.
- PHATHOM PHARMACEUTICALS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.86M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$132.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$7.05M 10-Q · filed 2026-07-30 | -$4.92M derived: sum of 3 quarters · filed 2026-07-30 | -$6.32M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$6.92M 10-Q · filed 2026-04-30 | -$4.79M derived: sum of 2 quarters · filed 2026-04-30 | -$6.18M derived: sum of 3 quarters · filed 2026-04-30 | -$4.62M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $2.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $733.00K derived: sum of 2 quarters · filed 2026-02-26 | $2.30M derived: sum of 3 quarters · filed 2026-07-30 | -$5.51M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $172.00K derived: sum of 2 quarters · filed 2026-07-30 | -$7.64M 10-Q · filed 2025-10-30 | -$1.75M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $1.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$6.25M 10-Q · filed 2026-07-30 | -$358.00K derived: sum of 3 quarters · filed 2026-07-30 | -$877.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$7.81M 10-Q · filed 2026-04-30 | -$1.92M derived: sum of 2 quarters · filed 2026-04-30 | -$2.44M derived: sum of 3 quarters · filed 2026-04-30 | $309.00K derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $5.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.37M derived: sum of 2 quarters · filed 2026-02-26 | $8.12M derived: sum of 3 quarters · filed 2026-02-26 | $7.67M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$519.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.23M derived: sum of 2 quarters · filed 2025-10-30 | $1.78M 10-Q · filed 2025-10-30 | $2.04M derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $2.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.30M 10-Q · filed 2025-08-07 | $2.56M derived: sum of 3 quarters · filed 2025-08-07 | $6.74M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$447.00K 10-Q · filed 2025-05-01 | -$193.00K derived: sum of 2 quarters · filed 2025-05-01 | $3.99M derived: sum of 3 quarters · filed 2025-05-01 | $2.48M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $4.43M derived: sum of 2 quarters · filed 2025-03-06 | $2.92M derived: sum of 3 quarters · filed 2025-03-06 | $8.07M 10-K · filed 2025-03-06 |
| 2023-09-30 | $4.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.67M derived: sum of 2 quarters · filed 2024-11-07 | $7.81M 10-Q · filed 2024-11-07 | $11.96M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.51M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-08-08 | $3.63M 10-Q · filed 2024-08-08 | $7.79M derived: sum of 3 quarters · filed 2024-08-08 | $6.89M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $5.14M 10-Q/A · filed 2024-06-14 | $9.29M derived: sum of 2 quarters · filed 2024-06-14 | $8.40M derived: sum of 3 quarters · filed 2024-06-14 | $2.62M derived: sum of 4 quarters · filed 2024-06-14 |
| 2022-12-31 | $4.15M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-06-14 | $3.26M derived: sum of 2 quarters · filed 2024-06-14 | -$2.52M derived: sum of 3 quarters · filed 2024-06-14 | $1.86M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | -$890.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$6.68M derived: sum of 2 quarters · filed 2023-11-09 | -$2.29M 10-Q · filed 2023-11-09 | $280.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | -$5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.40M 10-Q · filed 2023-08-10 | $1.17M derived: sum of 3 quarters · filed 2023-08-10 | $196.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $4.38M 10-Q · filed 2023-05-10 | $6.96M derived: sum of 2 quarters · filed 2023-05-10 | $5.98M derived: sum of 3 quarters · filed 2023-05-10 | $2.81M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.57M derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-02-28 | $1.60M derived: sum of 2 quarters · filed 2023-02-28 | -$1.57M derived: sum of 3 quarters · filed 2023-02-28 | -$605.00K 10-K · filed 2023-02-28 |
| 2021-09-30 | -$974.00K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2022-11-09 | -$4.14M derived: sum of 2 quarters · filed 2022-11-09 | -$3.18M 10-Q/A · filed 2022-11-09 | -$106.00K derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | -$2.20M 10-Q · filed 2022-08-02 | $868.00K derived: sum of 3 quarters · filed 2022-08-02 | $262.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $965.00K 10-Q · filed 2022-05-10 | $4.04M derived: sum of 2 quarters · filed 2022-05-10 | $3.43M derived: sum of 3 quarters · filed 2022-05-10 | -$318.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $2.46M derived: sum of 2 quarters · filed 2022-03-01 | -$1.28M derived: sum of 3 quarters · filed 2022-03-01 | -$7.96M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$606.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$4.35M derived: sum of 2 quarters · filed 2021-11-08 | -$11.03M 10-Q · filed 2021-11-08 | -$2.37M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | -$3.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$10.43M 10-Q · filed 2021-08-10 | -$1.76M derived: sum of 3 quarters · filed 2021-08-10 | -$217.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | -$6.68M 10-Q · filed 2021-05-11 | $1.99M derived: sum of 2 quarters · filed 2021-05-11 | $3.53M derived: sum of 3 quarters · filed 2021-05-11 | $5.01M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $8.67M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | $10.21M derived: sum of 2 quarters · filed 2021-03-30 | $11.69M derived: sum of 3 quarters · filed 2021-03-30 | $11.81M 10-K · filed 2021-03-30 |
| 2019-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $3.03M derived: sum of 2 quarters · filed 2020-11-10 | $3.15M 10-Q · filed 2020-11-10 | $3.13M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.60M 10-Q · filed 2020-08-06 | $1.59M derived: sum of 3 quarters · filed 2020-08-06 | |
| 2019-03-31 | $120.00K 10-Q · filed 2020-05-12 | $107.00K derived: sum of 2 quarters · filed 2020-05-12 | ||
| 2018-12-31 | -$13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $23.00K 10-K · filed 2020-03-19 | ||
| 2018-09-30 | $36.00K 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |